Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, tryz, BooDog, sox040713, 123tom, scottsmith
Search This Board: 
Last Post: 9/21/2018 11:11:58 AM - Followers: 755 - Board type: Free - Posts Today: 53

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Cannabis Report
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Annual Report (10-k) 09/11/2018 04:04:21 PM
IPIX News: Current Report Filing (8-k) 06/29/2018 02:11:50 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 06/29/2018 07:24:52 AM
IPIX News: Quarterly Report (10-q) 05/10/2018 04:14:20 PM
IPIX News: Traders News Issues Research on High Growth Canna and Pharma Stocks 04/25/2018 08:00:00 AM
PlusOneCoin Top Posts
#239252   lol. A for the ipix effort. TheHound 09/03/18 10:18:02 AM
#241173   "If a CRO issue, then communication by Leo rmzport 09/15/18 01:52:47 PM
#240802   You are reading it somewhat incorrectly. Term sheet PlentyParanoid 09/13/18 12:48:56 PM
PostSubject
#240994  Sticky Note Deal is in the works “The Company signed a Cherry_11 09/14/18 08:44:26 AM
#240968  Sticky Note I was also shocked and it hasn't dissipated. Detonate 09/14/18 05:51:10 AM
#235000  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 07/21/18 11:52:18 PM
#242168   Trust me, I don't spend a lot of Detonate 09/21/18 11:19:25 AM
#242167   This is an example of how active my Detonate 09/21/18 11:15:41 AM
#242166   LOL so true Pete, and there is one top123 09/21/18 11:12:05 AM
#242165   Just brutal price action again. OBV looks awful. MXAMDUD 09/21/18 11:11:58 AM
#242164   I had thought of this. And they Detonate 09/21/18 11:02:41 AM
#242163   Georgejji For how much? Echo20 09/21/18 11:01:50 AM
#242162   P could be better than existing formulas with Echo20 09/21/18 10:57:44 AM
#242161   Celgene knows and IPIX management knows that Prurisol georgejjl 09/21/18 10:52:52 AM
#242160   Celgene could buy or partner Prurisol and put groton68 09/21/18 10:49:59 AM
#242159   George, I understand all that. I would still groton68 09/21/18 10:48:39 AM
#242158   I agree with this. JPsooner 09/21/18 10:48:18 AM
#242157   Dare to compare Prurisol to Otezla (Apremilast) georgejjl 09/21/18 10:46:54 AM
#242156   Yesterday’s PR was reassuring and confidant. It certainly bradfordbros 09/21/18 10:40:43 AM
#242155   Celgene is not the right partner. They have groton68 09/21/18 10:39:30 AM
#242154   Do we expect a run up in the georgejjl 09/21/18 10:38:43 AM
#242152   True. Of course, we don't know what Leo JPsooner 09/21/18 10:35:07 AM
#242151   I would also keep an eye on insider JPsooner 09/21/18 10:32:53 AM
#242150   YES!!! Serious question. If Celgene were to buy out georgejjl 09/21/18 10:32:03 AM
#242149   That's a really good question. I'm not sure JPsooner 09/21/18 10:30:24 AM
#242148   Serious question. If Celgene were to buy Detonate 09/21/18 10:27:05 AM
#242147   I'd rather see partnership. Facebook bought Instagram for JPsooner 09/21/18 10:18:57 AM
#242146   Could Celgene outbid Novartis and Pfizer for Innovation Pharmaceuticals???[/b georgejjl 09/21/18 10:07:13 AM
#242145   Big bidder (71k) at .272. TheDane 09/21/18 10:05:13 AM
#242144   Celgene is definitely interested in buying Prurisol and/or georgejjl 09/21/18 10:01:33 AM
#242143   now down 9%. Leo Lucy strikes again. MXAMDUD 09/21/18 09:58:43 AM
#242142   Prurisol alone is worth at least $15 billion!!! georgejjl 09/21/18 09:49:15 AM
#242141   Someone said we open high close low? DaubersUP 09/21/18 09:47:09 AM
#242140   and down we go - as predicted. MXAMDUD 09/21/18 09:40:20 AM
#242139   Summary of Brilacidin-OM Phase 2 Study Results georgejjl 09/21/18 09:35:01 AM
#242138   What's next? Leo already set price at a To infinity and beyond! 09/21/18 09:33:26 AM
#242137   Top Contender: Innovation Pharmaceuticals (IPIX) georgejjl 09/21/18 09:30:46 AM
#242136   No, they are self proclaimed large shareholders yet petemantx 09/21/18 09:27:45 AM
#242135   .30 is the brick wall. We'll close MXAMDUD 09/21/18 09:27:43 AM
#242134   This article is much better imo... BooDog 09/21/18 09:13:43 AM
#242133   None. MackG 09/21/18 09:09:17 AM
#242132   The 10-K says: loanranger 09/21/18 08:53:04 AM
#242131   A number of "Pro" distorters active here imo. MackG 09/21/18 08:49:13 AM
#242130   You wouldn't have any personal experience related to Relentless4ever 09/21/18 08:38:38 AM
#242129   "If someone dubs himself a guru". Are Detonate 09/21/18 08:35:02 AM
#242128   Lame lame PR addressing nothing critical except the BTD. To infinity and beyond! 09/21/18 08:34:39 AM
#242127   Please go back and check the article against Jhawker 09/21/18 08:33:14 AM
#242126   Here is a good article that details the scottsmith 09/21/18 08:16:45 AM
#242125   The pace is about to pick up big BooDog 09/21/18 08:07:39 AM
#242124   cybermich, I hope a deal comes soon too. LilyGDog 09/21/18 07:44:14 AM
#242122   Just sell and call it a day. Save Here Today 09/21/18 07:30:48 AM
#242120   great thought but no liquidity to sell with MXAMDUD 09/21/18 07:01:26 AM
#242118  Restored without question. Leo Lucy will yank away MXAMDUD 09/21/18 06:09:11 AM
#242117  Restored All I can say is 123tom 09/21/18 01:20:34 AM
#242116   JTORENCE.. thanks for MAKING MY POINT.. cybermich 09/21/18 12:25:52 AM
#242114   Sell your shares. Pretty simple. Save the Cherry_11 09/20/18 11:04:40 PM
PostSubject